# Study Evaluating Mitoxantrone in Multiple Sclerosis

> **NCT00146159** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 336 (estimated)

## Conditions studied

- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT00146159
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2007-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146159, "Study Evaluating Mitoxantrone in Multiple Sclerosis". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00146159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*